|
|
|
| Efficacy and Immune Function of N-acetylcysteine Combined with Bi-PAP in Elderly COPD Patients with Respiratory Failure |
| LI Yanbin, YANG Menghong, WANG Fenli, et al |
| Department of Respiratory and Critical Care Medicine, Changqing Oilfield Workers' Hospital, Xi'an Shaanxi 710201 |
|
|
|
|
Abstract 【Objective】To investigate the efficacy of N-acetylcysteine combined with bilateral positive airway pressure (Bi-PAP) and its influence on immune function in the treatment of elderly chronic obstructive pulmonary disease (COPD) with respiratory failure.【Methods】Eighty elderly patients with COPD and respiratory failure admitted to our hospitals from January 2021 to January 2023 were selected and divided into the control group (receiving Bi-PAP therapy) and the observation group (receiving N-acetylcysteine therapy in addition to the control group) by random number table method. The differences in pulmonary function indicators (FEV1, FVC, FEV1/FVC), arterial blood gas analysis indicators (PaO2, PaCO2), immune function indicators (CD4+, CD8+, CD4+/CD8+), oxidative stress indicators (SOD, MDA), modified British Medical Research Council dyspnea index (mMRC) score, COPD Assessment Test (CAT) score, and incidence of adverse reactions were compared between the two groups.【Results】After treatment, the FVC, FEV1, FEV1/FVC, and PaO2 in the observation group were higher than those in the control group (P<0.05), and the PaCO2 in the observation group was lower than that in the control group (P<0.05). After treatment, the mMRC and CAT scores in the observation group were lower than those in the control group (P<0.05). After treatment, the CD4+ and CD4+/CD8+ in the observation group were higher than those in the control group, and the CD8+ was lower than that in the control group, with statistically significant differences (P<0.05). After treatment, the SOD in the observation group was higher than that in the control group, and the MDA was lower than that in the control group, with statistically significant differences (P<0.05). The total incidence of adverse reactions in the two groups was similar, with no statistically significant difference (P>0.05).【Conclusion】The combination of N-acetylcysteine and Bi-PAP therapy in elderly patients with COPD and respiratory failure can not only effectively improve their pulmonary function, dyspnea symptoms, arterial blood gas analysis indicators, and quality of life, but also improve their immune function and oxidative stress indicators. It has good safety.
|
|
Received: 27 May 2024
|
|
|
|
|
|
[1] 李萍,林桦,张爱丽,等.血清磷水平与老年慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭患者机械通气撤机结局的相关性分析[J].中华老年医学杂志,2020,39(6):613-617.
[2] 李鹏飞,刘利凯,张建华,等.N-乙酰半胱氨酸抗炎作用在慢性阻塞性肺疾病治疗中的研究及进展[J].临床肺科杂志,2022,27(2):285-289.
[3] 刘璐,李林,赖倩.双水平气道正压通气联合肺康复治疗慢性阻塞性肺病合并慢性呼吸衰竭患者的疗效观察[J].实用医院临床杂志,2020,17(4):194-197.
[4] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中华结核和呼吸杂志,2013,36(4):255-264.
[5] 陈灏珠,钟南山,陆再英.内科学[M].8版.北京:人民卫生出版社,2013:321-325.
[6] 田建霞,陈晓香,王继苹.改良英国医学研究委员会呼吸困难量表评分、慢性阻塞性肺疾病评估测试评分与慢性阻塞性肺疾病患者肺功能的相关性及其对肺动脉高压的预测价值[J].实用心脑肺血管病杂志,2018,26(12):44-48.
[7] 张勃,白吉明,王少飞,等.戒烟对COPD患者肺功能、CAT评分和急性发作的影响[J].重庆医学,2019,48(9):1527-1530.
[8] 李正欢,张晓云,陈杨,等.2020年慢性阻塞性肺疾病全球倡议《COPD诊断、治疗与预防全球策略》指南解读(一):稳定期药物管理[J].中国全科医学,2021,24(8):923-929.
[9] 魏胜全,薛华,王惠霞,等.罗红霉素联合N-乙酰半胱氨酸治疗慢性阻塞性肺疾病合并肺间质纤维化疗效及对患者肺功能的影响[J].陕西医学杂志,2020,49(5):611-614.
[10] 王亮,杨超,李玉静,等.莫达非尼联合Bi-PAP呼吸机治疗慢性阻塞性肺疾病合并睡眠呼吸暂停综合征的临床疗效[J].中国医学装备,2021,18(4):105-109.
[11] 康秀华.慢性阻塞性肺病合并Ⅱ型呼吸衰竭应用BI-PAP呼吸机的护理研究[J].生命科学仪器,2022,20(S01):52.
[12] 庞土富,苏伟强,吴桂清,等.N-乙酰半胱氨酸联合无创正压通气治疗COPD合并Ⅱ型呼吸衰竭的临床观察[J].广东医学院学报,2021,39(4):431-434.
[13] 胡红旗,王立丽,史家欣,等.无创正压通气(ST模式)联合乙酰半胱氨酸对COPD合并Ⅱ型呼衰患者的疗效及预后的影响分析[J].中国急救复苏与灾害医学杂志,2020,15(9):1085.
[14] 武秀亭,赵博.慢性阻塞性肺疾病患者的氧化应激改变与诊疗研究进展[J].实用临床医药杂志,2020,24(15):126-128.
[15] 王菲,李松.前列腺素E1联合瑞舒伐他汀在慢性阻塞性肺疾病合并肺动脉高压中应用对患者氧化应激反应、血管新生和NT-proBNP水平的影响[J].湖南师范大学学报(医学版),2020,17(2):152-156. |
|
|
|
2024, Vol. 41 
